Previous 10 | Next 10 |
2023-11-14 01:54:03 ET More on Kezar Life Sciences Kezar Life Sciences names new CEO, says to cut workforce by about 41% Seeking Alpha’s Quant Rating on Kezar Life Sciences Historical earnings data for Kezar Life Sciences Financial information for Keza...
Strategic restructuring extends cash runway to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis Collaboration and license agreement with Everest Medicines to develop and commercialize zetomipzomib in Greater China, South Korea and Southeast Asia ...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Kezar Life Sciences Inc. (KZR) is expected to report $-0.36 for Q3 2023
Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026 Co-Founder and Board Dire...
2023-09-24 22:33:00 ET Summary Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene...
Partnership with Everest Medicines will address a critical unmet medical need for patients with active lupus nephritis in Asia Kezar is eligible to receive up to $132.5 million in total payments, as well as tiered royalties Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinica...
2023-08-24 10:00:34 ET Gainers: CollPlant Biotechnologies ( CLGN ) +11% NeuBase Therapeutics ( NBSE ) +7% NeuroPace ( NPCE ) +7% Bionomics ( BNOX ) +6% Enhabit ( EHAB ) +16% Losers: NanoVibronix ( NAOV ) -15% ...
2023-08-11 10:14:56 ET Gainers: Eton Pharmaceuticals ( ETON ) +23% . Semler Scientific ( SMLR ) +20% . ModivCare ( MODV ) +15% . Erasca ( ERAS ) +9% . Relmada Therapeutics ( RLMD ) +8% . Losers: Cano Health ( CANO ) -...
2023-08-11 04:07:07 ET Kezar Life Sciences press release ( NASDAQ: KZR ): Q2 GAAP EPS of -$0.34 in-line. Cash, cash equivalents and marketable securities totaled $236.6 million as of June 30, 2023, compared to $276.6 million as of December 31, 2022. For further detai...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...